



FAQ

Is now a good time to invest in the pulmonary care industry?

The post-COVID economic downturn has led to reduced investment in biotherapeutics. This is an opportunity for investors to reevaluate where their investments most effectively lead to the development of advanced treatments. We believe that one of the areas that will emerge from this reevaluation, and has already gathered heightened public awareness, is respiratory medicine. Lung-related deaths now rival deaths from heart disease and cancer, due in part to a significant increase in the number of lung pathogens and environmental problems (e.g., smoke inhalation from wildfires, battlefield exposure, etc.). In addition to human loss, lung disease has a significant economic impact on the healthcare system.

What is unique about BioSuperior?

BioSuperior has developed a first-in-class synthetic pulmonary surfactant - BioSurf. Our patent-pending product will be used to treat patients who cannot breathe due to surfactant deficiency. It will also be used to deliver agents to the lungs to reduce inflammation, promote lung repair and fight adenocarcinoma, pulmonary hypertension, and interstitial lung fibrosis. BioSurf can be manufactured at scale and in stable form, making it more accessible to a broader patient population than existing animal-derived products. Our first drug candidate will be used for the treatment of Bronchopulmonary Dysplasia (BPD), an inflammatory disease that occurs in preterm infants.

What makes your team especially qualified?

Our team has the skills needed to develop innovative pharmaceutical products. Our collective efforts have resulted in products that have captured more than \$1B in annual revenue. We also have a team of scientific advisors that are well-respected pulmonologists and neonatologists.

How will the funds be used and what are your immediate next steps?

Since the inception of the company, we have garnered more than \$750,000 in early-stage funding, including grants from the March of Dimes and the National Science Foundation. With this money we have achieved the manufacture of our prototype surfactant. We are raising \$2,500,000 to complete key preclinical milestones, which will allow us to file for Orphan Drug Designation (ODD) and an IND for our first drug candidate aimed at treating BPD.

How will BioSurf be sold and administered, how much will it cost compared to other treatments?

Following regulatory approval, our initial BioSurf-based treatments will be sold to specialty pharma and ultimately administered by pulmonologists (neonatologists, respiratory therapists, and nurses) using existing methods for administering lung surfactant. We will also work with drug device manufacturers who are adapting nebulization for the delivery of lung surfactant-based products. Specific to the treatment of BPD in infants, reduced NICU days will significantly reduce hospital costs. In addition, lower morbidity will lower the overall healthcare burden due to hospital readmissions and in-home medical support.

How will patient eligibility be determined and what will be the process?

BPD is diagnosed at 36 weeks post-menstrual age (PMA), but neonatologists can identify this developing illness within 14 days of birth. BioSuperior plans to conduct clinical trials to demonstrate that our product significantly reduces the number of preterm infants that develop BPD. We expect BioSurf to far exceed the current standard of care. Through publications in respected journals and symposia, we are confident that hospitals and insurance companies will decide to list our drug on their formularies.

What other products is BioSuperior developing?

Beyond our BioSurf-based pipeline of products, the company plans to broaden its portfolio to include a gene-delivered therapeutic that will repair injured tissue. This therapeutic, Alveogene, is an exciting new treatment modality and has tremendous potential for the treatment of lung disease. Together with BioSurf, Alveogene will allow us to move from managing to curing serious lung disease.